Mounjaro (Tirzepatide) and Pancreatitis: Severity Grading Rubric

What the Mounjaro Label Says

Mounjaro is a once-weekly subcutaneous dual GIP and GLP-1 receptor agonist approved for type 2 diabetes in adults and children 10 years and older and for cardiovascular risk reduction in adults with type 2 diabetes; it is not labeled for weight loss [1]. Its pancreatitis warning contains no grading scale. The label says acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or MOUNJARO [1]. After starting Mounjaro, the label says to observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1]. If pancreatitis is suspected, the label says to discontinue MOUNJARO and initiate appropriate management [1].

The label ties its action to suspected pancreatitis rather than to a confirmed grade.

The Three Grades Clinicians Use

The revised Atlanta classification is an international consensus framework for acute pancreatitis [2]. It uses three categories:

• Mild acute pancreatitis has no organ failure and no local or systemic complications, and it usually resolves in the first week [2].
• Moderately severe acute pancreatitis has transient organ failure, local complications, or worsening of a coexisting medical condition [2].
• Severe acute pancreatitis has persistent organ failure, defined as organ failure lasting more than 48 hours [2].

The local complications named in the classification include peripancreatic fluid collections, pancreatic and peripancreatic necrosis that may be sterile or infected, pseudocyst, and walled-off necrosis that may be sterile or infected [2]. The framework exists for standardized reporting and communication between clinicians [2].

Does Tirzepatide Raise Pancreatitis Risk in Trials?

A 2023 systematic review and meta-analysis of nine randomized trials with 9,871 participants, including 6,828 on tirzepatide and 3,043 controls, found no significant increase in pancreatitis with tirzepatide (RR 1.46, 95% CI 0.59 to 3.61) [3]. The review found a higher rate of the combined gallbladder or biliary disease outcome with tirzepatide than with placebo or basal insulin (RR 1.97, 95% CI 1.14 to 3.42) [3]. The Mounjaro label separately warns about acute gallbladder disease, reported by 0.6% of Mounjaro-treated adults and 0% on placebo in its placebo-controlled trials, and says that if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated [1]. A separate 2025 meta-analysis of 21 trials and 99,599 patients found no difference in pancreatitis between GLP-1 receptor agonists, including tirzepatide, and controls [4].

These are group results. They do not diagnose an individual episode or assign a severity grade. The label warning remains the drug-specific instruction for a person taking Mounjaro [1].

Amylase and Lipase Are Not a Severity Score

The Mounjaro label notes that the clinical significance of pancreatic enzyme elevations is unknown without other signs or symptoms of pancreatitis [1]. A pooled analysis of four liraglutide weight-management trials with 5,358 participants found that amylase and lipase elevations had very low positive predictive value for acute pancreatitis, under 1% [5]. That analysis was for liraglutide, not tirzepatide, so it does not establish the same numbers for Mounjaro. It does support the narrower point that an isolated enzyme value and a symptomatic episode are different clinical problems.

A severity grade cannot be read directly from a lipase number. The revised Atlanta categories depend on organ failure and local complications, which are clinical and radiologic determinations [2].